Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (March 2022)
25 slides from Revelation Biosciences's investor presentation, Mar 15, 2022
Slide 1: Developing innovative therapeutics and diagnostics to address unmet needs
Developing innovative therapeutics and diagnostics to address unmet needs Corporate Presentation / March 2022 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended . Forward - looking statements are statements that are not historical facts . These forward - looking statements are generally identifi
Slide 3: Development Pipeline
Development Pipeline 3 Revelation is developing therapeutic and diagnostics base on modulation or measurement of the innate immune response Therapeutic Pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Approval REVTx - 99a REVTx - 99b REVTx - 200 Diagnostic Pipeline Research Development Clinica
Slide 4: Project Milestones
Project Milestones Project Milestone Estimated Timing REVTx - 99a: Intranasal solution for the prevention and/or treatment of respiratory viral infection • Preclinical data (in vitro) for SARS - CoV - 2 and variants x Q1 2022 • Preclinical data (in vivo) for SARS - CoV - 2 and variants Q2 2022 • Pha
Slide 5: Protective Cytokines: How Our Therapeutic Candidates Work
Protective Cytokines How Our Therapeutic Candidates Work • The active ingredient in our product candidates is Phosphorylated Hexa - Acyl Disaccharide ( PHAD) • We have developed propriety formulations to deliver the active ingredient to the local intran asal cavity • PHAD activates the local innate
Slide 6: Clinical Data Supports Our Proposed Mechanism of Action
Clinical Data Supports Our Proposed Mechanism of Action Safety x All doses of REVTx - 99 were well tolerated with no significant or serious adverse events x Drug related adverse events were all mild and limited to the local nasal mucosa and included runny nose or mild nasal congestion at the higher
Slide 7: REVTx-99a Intranasal Solution for the Prevention of Respiratory Viral Infection
REVTx - 99a Intranasal Solution for the Prevention of Respiratory Viral Infection
Slide 8: REVTx-99a Program Highlights
REVTx - 99a Program Highlights • REVTx - 99a has the potential to work broadly vs multiple virus types including influenza and SARS - COV - 2 • Based on a solid scientific foundation backed up by nonclinical and clinical data • IP covering formulations and methods of use filed • Multiple potentially
Slide 9: The Importance of Cytokines and Innate Immunity
The Importance of Cytokines and Innate Immunity 4 Emerging Microbes and Infections, Dec 11, 2019 DOI: 10.1080/22221751.2019.1698271 5 Journal of Biological Chemistry, June 25, 2020 DOI: 10.1074/jbc.AC120.013788 6 Vaccine, April 2010, DOI:10.1016/j.vaccine.2010.03.062 7 Bio. Pharmacology Vol. 183, Ja
Slide 10: Phase 2 Viral Challenge Study (De-Risking for Phase 3)
Phase 2 Viral Challenge Study (De - Risking for Phase 3) 10 Study Title: A Phase 2, study assessing prophylactic efficacy of intranasal REVTx - 99a in an H3N2 influenza challenge model in healthy humans • Total number of subjects: 30 (1:1 Placebo vs Treatment) • REVTx - 99a Day - 2 and Day - 1 (prio
Slide 11: Market Need: REVTx-99a has Multiple Possible Uses with Potentially Large Markets
Market Need: REVTx - 99a has Multiple Possible Uses with Potentially Large Markets 11 Seasonal virus prophylaxis (e.g. influenza season ) Seasonal Prophylaxis Potential Target Population At Risk Population. For example: • Health care workers • Elderly • Immunocompromised REVTx - 99 can be taken prop
Slide 12: REVTx-99 Value over Time (US)
REVTx - 99 Value over Time (US) 12 Near - Term Value Inflection Points In the US, RETv - 99 currently has a value of $131 M USD growing rapidly to $1.3 B USD in H2 2024 following FDA approval (Worldwide values are doubled given a standard two - times US to WW conversion factor) $131 $153 $459 $506 $
Slide 13: KOL Reactions to REVTx-99a
KOL Reactions to REVTx - 99a KOLs have favorable reactions to REVTx - 99a and were excited about its potential for use as a prevention for multiple types of viral infection 13 “It looks very compelling. It certainly addresses a lot of viral pathogens. The key one right now is COVID, but this potenti
Slide 14: REVTx-99b Intranasal Solution for the Prevention and/or Treatment of Chronic Nasal Congestion
REVTx - 99b Intranasal Solution For the Prevention and/or Treatment of Chronic Nasal Congestion
Slide 15: REVTx-99b Program Highlights
REVTx - 99b Program Highlights • New nonsteroidal therapies for allergies are urgently needed • Development rationale based on a solid scientific foundation • Eotaxin, an inflammatory cytokine, propagates allergies and inflammation through binding to the CCR3 receptor, which is expressed on a range
Slide 16: Phase 1b Nasal Challenge Study (RVL-CLR01)
Phase 1b Nasal Challenge Study (RVL - CLR01) Study Title: Effect of REVTx - 99b on Nasal Challenge with Allergen in Participants with Chronic Rhinosinusitis without Polyps Milestones • Enrollment up to 28 participants, randomized 1:1 across 4 cohorts • This will be a Phase 1b, randomized, double - b
Slide 17: REVTx-200 Intranasal Solution for Improved Intramuscular (IM) Vaccination
REVTx - 200 Intranasal Solution for Improved Intramuscular (IM) Vaccination
Slide 18: REVTx-200 Program Highlights
REVTx - 200 Program Highlights 18 x REVTx - 200 has the potential to be used with most respiratory viral vaccines currently in use or being developed » Identify and work with multiple partners with existing vaccines to evaluate REVTx - 200 nonclinically in 1H 2022 » Strong scientific advisory board
Slide 19: Phase 1 Clinical Data Supports Mechanism of Action
Phase 1 Clinical Data Supports Mechanism of Action MCP - 1 and IFN - ࢽ tracked with IP - 10 0 20 40 60 80 100 120 0 200 400 600 800 1000 1200 0 50 100 150 200 MCP - 1, IFN - g (pg/mL) IP10 (pg/mL) Time (hours) IP10-Right MCP1-Right IFN-g-Right 50 µg N: 11 Rate: 27% P: 0.05 0% 5% 10% 15% 20% 25% 30%
Slide 20: Strong Scientific Advisory Board Formed
Strong Scientific Advisory Board Formed Catherine Blish M.D., Ph.D. Dr. Blish is a Professor of Medicine and Immunology and the Associate Dean for Basic and Translational Research at the Stanford University School of Medicine . Her research is dedicated to learning how to harness the immune system t
Slide 21: REVDx-501 Rapid Testing Kit for Viral Infection
REVDx - 501 Rapid Testing kit for Viral Infection
Slide 22: REVDx-501: Rapid Test Kit for Viral Infection
REVDx - 501: Rapid Test Kit for Viral Infection • REVDx - 501 (REVID Œ ) is a diagnostic device in development for the detection of respiratory viral infection (SARS - CoV - 2, influenza A and B, parainfluenza, etc.) • REVDx - 501 detects IP - 10, a key cytokine that is upregulated in nasal and oral
Slide 23: Financial Overview
IVA REVELATION BaOFSIGHEINIG ES Financial Overview
Slide 24: Ownership, Cap Table and Financial Overview
24 Beneficial holders Percent George Tidmarsh, M.D., Ph.D. 13.5% All other management 11.0% Total management 24.5% AXA IM Prime Impact Fund 13.8% Petra Investment Holdings, LLC 12.4% Armistice Capital 9.1% LifeSci Venture Partners II, LP & Affiliates 7.3% Monashee Investments 6.4% Cap Table Shares C
Slide 25: Thank you!
For more information please visit www.revbiosciences.com Thank you!
Revelation Biosciences — Investor Presentation (March 2022) on 6ix